Crystal forms of tetrahydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine, processes of making such forms, and their pharmaceutical compositions
AssigneeAnavex Life Sciences Corp.
InventorsLinda Sharon Daintree, Daniel Mark Ledger, Lucy Anne Leonard, Peter York, Alani Selvey
Life of this patent
Estimating the term…
Abstract
Polymorphic forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) and a metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX19-144) are disclosed and characterized. Compositions and method for treatment of Alzheimer's disease that includes the polymorphic forms and metabolite of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73).
Claims20
A crystal form of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) made by crystallizing ANAVEX2-73 in a supercritical fluid (SCF) environment,
- wherein the supercritical fluid comprises supercritical carbon dioxide;
- and
- wherein the crystal form is substantially characterized by an X-ray diffraction pattern of FIG. 1, FIG. 4, or FIG. 8.
A method of making a crystal form of ANAVEX19-144 represented by Formula I, comprising crystallizing the ANAVEX19-144 in a supercritical fluid (SCF) environment.
Dependencies are inferred from the claim text.